AgomAb Therapeutics (NASDAQ:AGMB) Sees Large Volume Increase – Still a Buy?

AgomAb Therapeutics NV (NASDAQ:AGMB) saw strong trading volume on Friday . Approximately 265,532 shares were traded during mid-day trading, an increase of 103% from the previous session’s volume of 131,018 shares.The stock last traded at $13.8680 and had previously closed at $13.50.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on AGMB. HC Wainwright initiated coverage on AgomAb Therapeutics in a report on Monday, June 22nd. They set a “buy” rating and a $35.00 target price on the stock. B. Riley Financial began coverage on AgomAb Therapeutics in a research report on Thursday, July 23rd. They set a “buy” rating and a $34.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, AgomAb Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $33.00.

AgomAb Therapeutics Stock Performance

The company has a current ratio of 6.52, a quick ratio of 6.52 and a debt-to-equity ratio of 0.01. The stock has a 50-day moving average price of $12.24.

AgomAb Therapeutics (NASDAQ:AGMB) last posted its earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. Analysts predict that AgomAb Therapeutics NV will post -1.84 EPS for the current year.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.